Australia - englanti - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salmeterol xinafoate, quantity: 72.5 microgram/actuation (equivalent: salmeterol, qty 50 microgram/actuation); fluticasone propionate, quantity: 500 microgram/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. pavtide is not indicated for the initiation of bronchodilator therapy in copd.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 250 microgram/actuation; salmeterol xinafoate, quantity: 72.5 microgram/actuation (equivalent: salmeterol, qty 50 microgram/actuation) - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. pavtide is not indicated for the initiation of bronchodilator therapy in copd.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salmeterol xinafoate, quantity: 72.5 microgram/actuation (equivalent: salmeterol, qty 50 microgram/actuation); fluticasone propionate, quantity: 100 microgram/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta-2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,*initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on "as needed" reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring medication every day (see clinical trials).,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. pavtide is not indicated for the initiation of bronchodilator therapy in copd.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - levothyroxine sodium, quantity: 50 microgram - tablet - excipient ingredients: colloidal anhydrous silica; maize starch; purified talc; microcrystalline cellulose; magnesium stearate - eltroxin is indicated for the management of demonstrated thyroid hormone deficiency.,eltroxin is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Yhdysvallat - englanti - NLM (National Library of Medicine)

ahava - dead sea laboratories ltd. - octocrylene (unii: 5a68wgf6wm) (octocrylene - unii:5a68wgf6wm), ensulizole (unii: 9yq9di1w42) (ensulizole - unii:9yq9di1w42), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w), avobenzone (unii: g63qqf2nox) (avobenzone - unii:g63qqf2nox), titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp) - octocrylene 25 ml in 250 ml - purpose   sunscreen uses     * helps prevent sunburn     * higher spf gives more sunburn protection

Yhdysvallat - englanti - NLM (National Library of Medicine)

pure source, llc - titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp), zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - titanium dioxide 60 mg in 1 ml - - helps prevent sunburn - if used as directed with other sun protection measures (see directions), sunscreen decreases the risk of skin cancer and early skin aging caused by the sun.

Yhdysvallat - englanti - NLM (National Library of Medicine)

la prairie - active ingredients purpose, octinoxate 7.5% sunscreen, oxybenzone 5.0% sunscreen, titanium dioxide 1.9% sunscreen, zinc oxide18.6% sunscreen - sunscreen helps prevent sunburn on damaged or broken skin if rash occurs

Yhdysvallat - englanti - NLM (National Library of Medicine)

siborg - zinc oxide 14% - sunscreen - helps prevent sunburn - if used as directed with other sun protection measures ( see directions ), decreases the risk of skin cancer and early skin aging caused by the sun

Yhdysvallat - englanti - NLM (National Library of Medicine)

agrilabs - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - for use as an aid in the treatment of acetonemia (ketosis) in cattle.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 50 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: *patients on effective maintenance doses of long-acting beta-2-agonists and inhaled corticosteroids. *patients who are symptomatic on current inhaled corticosteroid therapy.*initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on "as needed" reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring medication every day (see clinical trials). for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. seretide is not indicated for the initiation of bronchodilator therapy in copd.